Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477490 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
A Phase 3 study of Nocturia, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 799
- Enrollment target
- 20
- Study locations
NCT00477490 is a Phase 3 study of Nocturia that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 799 participants, above the 228-participant average among 9 other Nocturia trials with a reported enrollment target (250% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT00477490, a Phase 3 study of Nocturia, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 799 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of several doses of the melt formulation of desmopressin in a broad population of adult patients with nocturia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG desmopressin acetate
Study Locations (20)
California
- Advanced Urology Medical Center - Anaheim
- Impact Clinical Trials - Beverly Hills
- Atlantic Urology Medical Group - Long Beach
- California Professional Research - Newport Beach
- San Diego Uro-Research - San Diego
- Radiant Research - Santa Rosa
- West Coast Clinical Research - Tarzana
- Western Clinical Research - Torrance
Florida
- South Florida Medical Research - Aventura
- Women's Medical Research Group, LLC - Clearwater
- Medsearch Professional Group - Miami
- Sunrise Medical Research - Plantation
- Radiant Research - Stuart
Colorado
- Urology Associates PC - Denver
- Downtown Women's Health Care - Denver
- Genitourinary Surgical Consultants - Denver
Alabama
- Radiant Research - Birmingham
Arizona
- Radiant Research - Scottsdale
Arkansas
- Arkansas Primary Care Clinic - Little Rock
Connecticut
- Connecticut Clinical Research Center, LLC - Middlebury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 799 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477490
The ClinicalTrials.gov registry entry for NCT00477490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 799 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 228-participant average among 9 other Nocturia trials with a reported enrollment target (250% higher). The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nocturia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00477490 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00477490 about?
NCT00477490 is a clinical study titled "Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia". The purpose of this study is to investigate the efficacy and safety of several doses of the melt formulation of desmopressin in a broad population of adult patients with nocturia.
What is the current status of trial NCT00477490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 799 participants. The study started on 2007-05. Estimated completion is 2008-02.
What conditions does trial NCT00477490 study?
This clinical trial studies the following conditions: Nocturia.
What interventions are being tested in trial NCT00477490?
The interventions under investigation include: Placebo (DRUG), desmopressin acetate (DRUG).
Who is sponsoring clinical trial NCT00477490?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00477490 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nocturia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
COMPLETED · Phase 3
-
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
COMPLETED · Phase 3
-
Long Term Safety Assessment of SER120 in Patients With Nocturia
COMPLETED · Phase 3
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.